PCSK 9 Inhibitors -Pipeline Insights, 2015” – A DelveInsight’s Report

NEW DELHI - Aug. 5, 2015 - PRLog -- The PCSK9 Inhibitors - Pipeline Insights, 2015 report provides client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes:

· The report gives information of 25+ pipeline drugs with 17+ companies actively involved in drug development. There are 3 drugs in discovery, 8 in pre-clinical, 6 in phase I, 2 in phase II and 1 in phase III.

· Pfizer is developing a lead product Bococizumab which is in Phase III.

· R&D activities and technologies used along with the pipeline molecules in development.

· Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

· Information related to collaborations, in-licensing and out-licensing deals.

DelveInsights, PCSK9 Inhibitors - Pipeline Insights, 2015 report provides PCSK9 InhibitorsLandscape across the globe. Therefore the report on PCSK9 Inhibitors - Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com